{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:11:29Z","timestamp":1789665089974,"version":"4.0.1"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40266-026-01287-9","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T13:59:48Z","timestamp":1772200788000},"page":"211-221","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Treating Genitourinary Syndrome of Menopause in Postmenopausal Women with a History of Breast Cancer"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2089-8283","authenticated-orcid":false,"given":"Dewonna","family":"Ferguson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4325-8370","authenticated-orcid":false,"given":"Holly","family":"Pederson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9898-8405","authenticated-orcid":false,"given":"Juliana M.","family":"Kling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"1287_CR1","doi-asserted-by":"publisher","unstructured":"The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976\u201392. https:\/\/doi.org\/10.1097\/gme.0000000000001609.","DOI":"10.1097\/gme.0000000000001609"},{"key":"1287_CR2","doi-asserted-by":"publisher","DOI":"10.1097\/gme.0000000000002617","author":"J Karam","year":"2025","unstructured":"Karam J, Shufelt C, Kingsberg S, et al. Understanding the sexual concerns of older women presenting for care to women\u2019s health clinics: a cross-sectional study. Menopause. 2025. https:\/\/doi.org\/10.1097\/gme.0000000000002617.","journal-title":"Menopause"},{"key":"1287_CR3","unstructured":"American Cancer Society. Breast cancer facts & figures 2024\u20132025. 2024. https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/breast-cancer-facts-figures.html."},{"issue":"4","key":"1287_CR4","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3322\/caac.70011","volume":"75","author":"NS Wagle","year":"2025","unstructured":"Wagle NS, Nogueira L, Devasia TP, et al. Cancer treatment and survivorship statistics, 2025. CA Cancer J Clin. 2025;75(4):308\u201340. https:\/\/doi.org\/10.3322\/caac.70011.","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"1287_CR5","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.clbc.2017.05.008","volume":"17","author":"N Biglia","year":"2017","unstructured":"Biglia N, Bounous VE, D\u2019Alonzo M, et al. Vaginal atrophy in breast cancer survivors: attitude and approaches among oncologists. Clin Breast Cancer. 2017;17(8):611\u20137. https:\/\/doi.org\/10.1016\/j.clbc.2017.05.008.","journal-title":"Clin Breast Cancer"},{"issue":"6","key":"1287_CR6","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1111\/jsm.12120","volume":"10","author":"SA Kingsberg","year":"2013","unstructured":"Kingsberg SA, Krychman ML. Resistance and barriers to local estrogen therapy in women with atrophic vaginitis. J Sex Med. 2013;10(6):1567\u201374. https:\/\/doi.org\/10.1111\/jsm.12120.","journal-title":"J Sex Med"},{"key":"1287_CR7","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Survivorship. Version 2.2025. 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/survivorship.pdf."},{"issue":"6","key":"1287_CR8","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1097\/gme.0000000000001121","volume":"25","author":"SS Faubion","year":"2018","unstructured":"Faubion SS, Larkin LC, Stuenkel CA, et al. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women\u2019s Sexual Health. Menopause. 2018;25(6):596\u2013608. https:\/\/doi.org\/10.1097\/gme.0000000000001121.","journal-title":"Menopause"},{"issue":"6","key":"1287_CR9","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s12282-021-01260-x","volume":"28","author":"A Pearson","year":"2021","unstructured":"Pearson A, Dhillon HM, Kiely BE. Genitourinary symptoms in women with breast cancer: what do oncology health professionals think and do about them? Breast Cancer. 2021;28(6):1243\u201351. https:\/\/doi.org\/10.1007\/s12282-021-01260-x.","journal-title":"Breast Cancer"},{"issue":"2","key":"1287_CR10","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1097\/gme.0000000000001194","volume":"26","author":"SA Kingsberg","year":"2019","unstructured":"Kingsberg SA, Larkin L, Krychman M, Parish SJ, Bernick B, Mirkin S. WISDOM survey: attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer history. Menopause. 2019;26(2):124\u201331. https:\/\/doi.org\/10.1097\/gme.0000000000001194.","journal-title":"Menopause"},{"issue":"4","key":"1287_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-025-09297-w","volume":"33","author":"A Pearson","year":"2025","unstructured":"Pearson A, Dhillon HM, Chen J, et al. Genitourinary symptoms in women with breast cancer: frequency, severity and impact. Support Care Cancer. 2025;33(4):258. https:\/\/doi.org\/10.1007\/s00520-025-09297-w.","journal-title":"Support Care Cancer"},{"issue":"3","key":"1287_CR12","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jsxm.2017.01.011","volume":"14","author":"M Krychman","year":"2017","unstructured":"Krychman M, Graham S, Bernick B, Mirkin S, Kingsberg SA. The Women\u2019s EMPOWER Survey: Women\u2019s knowledge and awareness of treatment options for vulvar and vaginal atrophy remains inadequate. J Sex Med. 2017;14(3):425\u201333. https:\/\/doi.org\/10.1016\/j.jsxm.2017.01.011.","journal-title":"J Sex Med"},{"issue":"7","key":"1287_CR13","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1111\/jsm.12190","volume":"10","author":"SA Kingsberg","year":"2013","unstructured":"Kingsberg SA, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women\u2019s VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med. 2013;10(7):1790\u20139. https:\/\/doi.org\/10.1111\/jsm.12190.","journal-title":"J Sex Med"},{"issue":"10","key":"1287_CR14","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1097\/GME.0b013e318287342d","volume":"20","author":"JA Simon","year":"2013","unstructured":"Simon JA, Kokot-Kierepa M, Goldstein J, Nappi RE. Vaginal health in the United States: results from the Vaginal Health: Insights, Views & Attitudes survey. Menopause. 2013;20(10):1043\u20138. https:\/\/doi.org\/10.1097\/GME.0b013e318287342d.","journal-title":"Menopause"},{"issue":"3","key":"1287_CR15","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1089\/jwh.2009.1384","volume":"19","author":"I Goldstein","year":"2010","unstructured":"Goldstein I. Recognizing and treating urogenital atrophy in postmenopausal women. J Womens Health. 2010;19(3):425\u201332. https:\/\/doi.org\/10.1089\/jwh.2009.1384.","journal-title":"J Womens Health"},{"key":"1287_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00181","volume":"5","author":"E Amabebe","year":"2018","unstructured":"Amabebe E, Anumba DOC. The vaginal microenvironment: the physiologic role of lactobacilli. Front Med (Lausanne). 2018;5:181. https:\/\/doi.org\/10.3389\/fmed.2018.00181.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"1287_CR17","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3109\/13697137.2015.1078206","volume":"18","author":"J Calleja-Agius","year":"2015","unstructured":"Calleja-Agius J, Brincat MP. The urogenital system and the menopause. Climacteric. 2015;18(1):18\u201322. https:\/\/doi.org\/10.3109\/13697137.2015.1078206.","journal-title":"Climacteric"},{"issue":"4","key":"1287_CR18","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1001\/jama.1982.03330040033027","volume":"248","author":"JP Semmens","year":"1982","unstructured":"Semmens JP, Wagner G. Estrogen deprivation and vaginal function in postmenopausal women. JAMA. 1982;248(4):445\u20138.","journal-title":"JAMA"},{"issue":"4","key":"1287_CR19","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1177\/1754045313511398","volume":"19","author":"D Robinson","year":"2013","unstructured":"Robinson D, Toozs-Hobson P, Cardozo L. The effect of hormones on the lower urinary tract. Menopause Int. 2013;19(4):155\u201362. https:\/\/doi.org\/10.1177\/1754045313511398.","journal-title":"Menopause Int"},{"key":"1287_CR20","doi-asserted-by":"publisher","DOI":"10.1097\/ju.0000000000004589","author":"MR Kaufman","year":"2025","unstructured":"Kaufman MR, Ackerman AL, Amin KA, et al. The AUA\/SUFU\/AUGS guideline on genitourinary syndrome of menopause. J Urol. 2025. https:\/\/doi.org\/10.1097\/ju.0000000000004589.","journal-title":"J Urol"},{"issue":"9324","key":"1287_CR21","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1016\/s0140-6736(02)09088-8","volume":"359","author":"M Baum","year":"2002","unstructured":"Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359(9324):2131\u20139. https:\/\/doi.org\/10.1016\/s0140-6736(02)09088-8.","journal-title":"Lancet"},{"issue":"2","key":"1287_CR22","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3390\/jpm5020050","volume":"5","author":"J Lester","year":"2015","unstructured":"Lester J, Pahouja G, Andersen B, Lustberg M. Atrophic vaginitis in breast cancer survivors: a difficult survivorship issue. J Pers Med. 2015;5(2):50\u201366. https:\/\/doi.org\/10.3390\/jpm5020050.","journal-title":"J Pers Med"},{"issue":"1","key":"1287_CR23","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/13697130500487224","volume":"9","author":"P Gupta","year":"2006","unstructured":"Gupta P, Sturdee DW, Palin SL, et al. Menopausal symptoms in women treated for breast cancer: the prevalence and severity of symptoms and their perceived effects on quality of life. Climacteric. 2006;9(1):49\u201358. https:\/\/doi.org\/10.1080\/13697130500487224.","journal-title":"Climacteric"},{"issue":"1","key":"1287_CR24","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1177\/0193945910391483","volume":"34","author":"J Lester","year":"2012","unstructured":"Lester J, Bernhard L, Ryan-Wenger N. A self-report instrument that describes urogenital atrophy symptoms in breast cancer survivors. West J Nurs Res. 2012;34(1):72\u201396. https:\/\/doi.org\/10.1177\/0193945910391483.","journal-title":"West J Nurs Res"},{"issue":"8","key":"1287_CR25","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1200\/jco.1999.17.8.2365","volume":"17","author":"PJ Goodwin","year":"1999","unstructured":"Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999;17(8):2365\u201370. https:\/\/doi.org\/10.1200\/jco.1999.17.8.2365.","journal-title":"J Clin Oncol"},{"key":"1287_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.572388","volume":"11","author":"D Mauri","year":"2020","unstructured":"Mauri D, Gazouli I, Zarkavelis G, et al. Chemotherapy associated ovarian failure. Front Endocrinol (Lausanne). 2020;11:572388. https:\/\/doi.org\/10.3389\/fendo.2020.572388.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"1287_CR27","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1177\/107327480200900603","volume":"9","author":"SE Minton","year":"2002","unstructured":"Minton SE, Munster PN. Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control. 2002;9(6):466\u201372. https:\/\/doi.org\/10.1177\/107327480200900603.","journal-title":"Cancer Control"},{"key":"1287_CR28","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Breast Cancer. Version 4.2025. 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pd."},{"issue":"3","key":"1287_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2837","volume":"13","author":"MM Regan","year":"2011","unstructured":"Regan MM, Price KN, Giobbie-Hurder A, Th\u00fcrlimann B, Gelber RD. Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer. Breast Cancer Res. 2011;13(3):209. https:\/\/doi.org\/10.1186\/bcr2837.","journal-title":"Breast Cancer Res"},{"issue":"26","key":"1287_CR30","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1056\/NEJMoa052258","volume":"353","author":"B Th\u00fcrlimann","year":"2005","unstructured":"Th\u00fcrlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353(26):2747\u201357. https:\/\/doi.org\/10.1056\/NEJMoa052258.","journal-title":"N Engl J Med"},{"issue":"5","key":"1287_CR31","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1200\/jco.2006.08.8617","volume":"25","author":"AS Coates","year":"2007","unstructured":"Coates AS, Keshaviah A, Th\u00fcrlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007;25(5):486\u201392. https:\/\/doi.org\/10.1200\/jco.2006.08.8617.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1287_CR32","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/s1470-2045(07)70385-6","volume":"9","author":"JF Forbes","year":"2008","unstructured":"Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9(1):45\u201353. https:\/\/doi.org\/10.1016\/s1470-2045(07)70385-6.","journal-title":"Lancet Oncol"},{"key":"1287_CR33","doi-asserted-by":"publisher","unstructured":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341\u201352. https:\/\/doi.org\/10.1016\/s0140-6736(15)61074-1.","DOI":"10.1016\/s0140-6736(15)61074-1"},{"issue":"7","key":"1287_CR34","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1200\/jco.2010.33.7899","volume":"30","author":"JM Bliss","year":"2012","unstructured":"Bliss JM, Kilburn LS, Coleman RE, et al. Disease-related outcomes with long-term follow-up: an updated analysis of the Intergroup Exemestane Study. J Clin Oncol. 2012;30(7):709\u201317. https:\/\/doi.org\/10.1200\/jco.2010.33.7899.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1287_CR35","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/nrc2683","volume":"9","author":"JM Hoskins","year":"2009","unstructured":"Hoskins JM, Carey LA, McLeod HL. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer. 2009;9(8):576\u201386. https:\/\/doi.org\/10.1038\/nrc2683.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"1287_CR36","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1093\/jnci\/86.7.527","volume":"86","author":"B Fisher","year":"1994","unstructured":"Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 1994;86(7):527\u201337. https:\/\/doi.org\/10.1093\/jnci\/86.7.527.","journal-title":"J Natl Cancer Inst"},{"issue":"13","key":"1287_CR37","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1056\/nejm199203263261302","volume":"326","author":"RR Love","year":"1992","unstructured":"Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 1992;326(13):852\u20136. https:\/\/doi.org\/10.1056\/nejm199203263261302.","journal-title":"N Engl J Med"},{"issue":"3","key":"1287_CR38","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s10549-006-9260-6","volume":"100","author":"D Cella","year":"2006","unstructured":"Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A. Quality of life of postmenopausal women in the ATAC (\u201cArimidex\u201d, tamoxifen, alone or in combination) trial after completion of 5 years\u2019 adjuvant treatment for early breast cancer. Breast Cancer Res Treat. 2006;100(3):273\u201384. https:\/\/doi.org\/10.1007\/s10549-006-9260-6.","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"1287_CR39","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1200\/jco.22.01064","volume":"41","author":"O Pagani","year":"2023","unstructured":"Pagani O, Walley BA, Fleming GF, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer: long-term follow-up of the combined TEXT and SOFT Trials. J Clin Oncol. 2023;41(7):1376\u201382. https:\/\/doi.org\/10.1200\/jco.22.01064.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1287_CR40","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3816\/CBC.2009.n.020","volume":"9","author":"SN Chin","year":"2009","unstructured":"Chin SN, Trinkaus M, Simmons C, et al. Prevalence and severity of urogenital symptoms in postmenopausal women receiving endocrine therapy for breast cancer. Clin Breast Cancer. 2009;9(2):108\u201317. https:\/\/doi.org\/10.3816\/CBC.2009.n.020.","journal-title":"Clin Breast Cancer"},{"issue":"7","key":"1287_CR41","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1016\/s1470-2045(20)30741-5","volume":"22","author":"L Biganzoli","year":"2021","unstructured":"Biganzoli L, Battisti NML, Wildiers H, et al. Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG). Lancet Oncol. 2021;22(7):e327\u201340. https:\/\/doi.org\/10.1016\/s1470-2045(20)30741-5.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1287_CR42","doi-asserted-by":"publisher","DOI":"10.1080\/26410397.2022.2044198","volume":"29","author":"CE Kennedy","year":"2021","unstructured":"Kennedy CE, Yeh PT, Li J, Gonsalves L, Narasimhan M. Lubricants for the promotion of sexual health and well-being: a systematic review. Sex Reprod Health Matters. 2021;29(3):2044198. https:\/\/doi.org\/10.1080\/26410397.2022.2044198.","journal-title":"Sex Reprod Health Matters"},{"issue":"1","key":"1287_CR43","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/s0015-0282(16)56474-7","volume":"61","author":"LE Nachtigall","year":"1994","unstructured":"Nachtigall LE. Comparative study: Replens versus local estrogen in menopausal women. Fertil Steril. 1994;61(1):178\u201380. https:\/\/doi.org\/10.1016\/s0015-0282(16)56474-7.","journal-title":"Fertil Steril"},{"issue":"3","key":"1287_CR44","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1200\/jco.1997.15.3.969","volume":"15","author":"CL Loprinzi","year":"1997","unstructured":"Loprinzi CL, Abu-Ghazaleh S, Sloan JA, et al. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. J Clin Oncol. 1997;15(3):969\u201373. https:\/\/doi.org\/10.1200\/jco.1997.15.3.969.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1287_CR45","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1111\/jsm.12156","volume":"10","author":"I Juraskova","year":"2013","unstructured":"Juraskova I, Jarvis S, Mok K, et al. The acceptability, feasibility, and efficacy (phase I\/II study) of the OVERcome (Olive Oil, Vaginal Exercise, and MoisturizeR) intervention to improve dyspareunia and alleviate sexual problems in women with breast cancer. J Sex Med. 2013;10(10):2549\u201358. https:\/\/doi.org\/10.1111\/jsm.12156.","journal-title":"J Sex Med"},{"issue":"2","key":"1287_CR46","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/jsm.12022","volume":"10","author":"KN Jozkowski","year":"2013","unstructured":"Jozkowski KN, Herbenick D, Schick V, Reece M, Sanders SA, Fortenberry JD. Women\u2019s perceptions about lubricant use and vaginal wetness during sexual activities. J Sex Med. 2013;10(2):484\u201392. https:\/\/doi.org\/10.1111\/jsm.12022.","journal-title":"J Sex Med"},{"issue":"3","key":"1287_CR47","doi-asserted-by":"publisher","first-page":"530","DOI":"10.3390\/pharmaceutics6030530","volume":"6","author":"AR Cunha","year":"2014","unstructured":"Cunha AR, Machado RM, Palmeira-de-Oliveira A, Martinez-de-Oliveira J, das Neves J, Palmeira-de-Oliveira R. Characterization of commercially available vaginal lubricants: a safety perspective. Pharmaceutics. 2014;6(3):530\u201342. https:\/\/doi.org\/10.3390\/pharmaceutics6030530.","journal-title":"Pharmaceutics"},{"issue":"3","key":"1287_CR48","first-page":"562","volume":"33","author":"Organization WH","year":"2019","unstructured":"Organization WH. WHO\/United Nations Population Fund (UNFPA) specifications for plain lubricants. WHO Drug Inf. 2019;33(3):562\u201372.","journal-title":"WHO Drug Inf"},{"issue":"1","key":"1287_CR49","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/13697137.2020.1820478","volume":"24","author":"N Potter","year":"2021","unstructured":"Potter N, Panay N. Vaginal lubricants and moisturizers: a review into use, efficacy, and safety. Climacteric. 2021;24(1):19\u201324. https:\/\/doi.org\/10.1080\/13697137.2020.1820478.","journal-title":"Climacteric"},{"issue":"6","key":"1287_CR50","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1111\/jsm.12125","volume":"10","author":"J Chen","year":"2013","unstructured":"Chen J, Geng L, Song X, Li H, Giordan N, Liao Q. Evaluation of the efficacy and safety of hyaluronic acid vaginal gel to ease vaginal dryness: a multicenter, randomized, controlled, open-label, parallel-group, clinical trial. J Sex Med. 2013;10(6):1575\u201384. https:\/\/doi.org\/10.1111\/jsm.12125.","journal-title":"J Sex Med"},{"key":"1287_CR51","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejogrb.2018.08.008","volume":"229","author":"E Pitsouni","year":"2018","unstructured":"Pitsouni E, Grigoriadis T, Douskos A, Kyriakidou M, Falagas ME, Athanasiou S. Efficacy of vaginal therapies alternative to vaginal estrogens on sexual function and orgasm of menopausal women: a systematic review and meta-analysis of randomized controlled trials. Eur J Obstet Gynecol Reprod Biol. 2018;229:45\u201356. https:\/\/doi.org\/10.1016\/j.ejogrb.2018.08.008.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"4","key":"1287_CR52","first-page":"321","volume":"64","author":"EF Grimaldi","year":"2012","unstructured":"Grimaldi EF, Restaino S, Inglese S, et al. Role of high molecular weight hyaluronic acid in postmenopausal vaginal discomfort. Minerva Ginecol. 2012;64(4):321\u20139.","journal-title":"Minerva Ginecol"},{"issue":"3","key":"1287_CR53","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00404-010-1382-8","volume":"283","author":"M Ekin","year":"2011","unstructured":"Ekin M, Ya\u015far L, Savan K, et al. The comparison of hyaluronic acid vaginal tablets with estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Arch Gynecol Obstet. 2011;283(3):539\u201343. https:\/\/doi.org\/10.1007\/s00404-010-1382-8.","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"1287_CR54","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00520-020-05472-3","volume":"29","author":"J Carter","year":"2021","unstructured":"Carter J, Baser RE, Goldfrank DJ, et al. A single-arm, prospective trial investigating the effectiveness of a non-hormonal vaginal moisturizer containing hyaluronic acid in postmenopausal cancer survivors. Support Care Cancer. 2021;29(1):311\u201322. https:\/\/doi.org\/10.1007\/s00520-020-05472-3.","journal-title":"Support Care Cancer"},{"issue":"5","key":"1287_CR55","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1097\/aog.0000000000001988","volume":"129","author":"YH Kim","year":"2017","unstructured":"Kim YH, Park S, Lee M, Hahn S, Jeon MJ. Effect of a pH-balanced vaginal gel on dyspareunia and sexual function in breast cancer survivors who were premenopausal at diagnosis: a randomized controlled trial. Obstet Gynecol. 2017;129(5):870\u20136. https:\/\/doi.org\/10.1097\/aog.0000000000001988.","journal-title":"Obstet Gynecol"},{"issue":"4","key":"1287_CR56","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1097\/AOG.0b013e3182118790","volume":"117","author":"YK Lee","year":"2011","unstructured":"Lee YK, Chung HH, Kim JW, Park NH, Song YS, Kang SB. Vaginal pH-balanced gel for the control of atrophic vaginitis among breast cancer survivors: a randomized controlled trial. Obstet Gynecol. 2011;117(4):922\u20137. https:\/\/doi.org\/10.1097\/AOG.0b013e3182118790.","journal-title":"Obstet Gynecol"},{"issue":"4","key":"1287_CR57","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1007\/s00520-019-04684-6","volume":"27","author":"Z Keshavarzi","year":"2019","unstructured":"Keshavarzi Z, Janghorban R, Alipour S, Tahmasebi S, Jokar A. The effect of vitamin D and E vaginal suppositories on tamoxifen-induced vaginal atrophy in women with breast cancer. Support Care Cancer. 2019;27(4):1325\u201334. https:\/\/doi.org\/10.1007\/s00520-019-04684-6.","journal-title":"Support Care Cancer"},{"issue":"30","key":"1287_CR58","doi-asserted-by":"publisher","first-page":"3394","DOI":"10.1200\/jco.2014.60.7366","volume":"33","author":"MF Goetsch","year":"2015","unstructured":"Goetsch MF, Lim JY, Caughey AB. A practical solution for dyspareunia in breast cancer survivors: a randomized controlled trial. J Clin Oncol. 2015;33(30):3394\u2013400. https:\/\/doi.org\/10.1200\/jco.2014.60.7366.","journal-title":"J Clin Oncol"},{"key":"1287_CR59","unstructured":"FDA Warns Against Use of Energy-Based devices to perform vaginal \u2018rejuvenation\u2019 or vaginal cosmetic procedures: FDA Safety Communication. July 30, 2018. Updated November 20, 2018. https:\/\/www.fda.gov\/medicaldevices\/safety\/alertsandnotices\/ucm615013.htm."},{"issue":"14","key":"1287_CR60","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1001\/jama.2021.14892","volume":"326","author":"FG Li","year":"2021","unstructured":"Li FG, Maheux-Lacroix S, Deans R, Nesbitt-Hawes E, Budden A, Nguyen K, et al. Effect of fractional carbon dioxide laser vs sham treatment on symptom severity in women with postmenopausal vaginal symptoms: a randomized clinical trial. JAMA. 2021;326(14):1381\u20139. https:\/\/doi.org\/10.1001\/jama.2021.14892.","journal-title":"JAMA"},{"issue":"1","key":"1287_CR61","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/gme.0000000000000955","volume":"25","author":"VL Cruz","year":"2018","unstructured":"Cruz VL, Steiner ML, Pompei LM, et al. Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women. Menopause. 2018;25(1):21\u20138. https:\/\/doi.org\/10.1097\/gme.0000000000000955.","journal-title":"Menopause"},{"issue":"4","key":"1287_CR62","doi-asserted-by":"publisher","first-page":"e556","DOI":"10.1016\/j.clbc.2019.04.007","volume":"19","author":"S Jha","year":"2019","unstructured":"Jha S, Wyld L, Krishnaswamy PH. The impact of vaginal laser treatment for genitourinary syndrome of menopause in breast cancer survivors: a systematic review and meta-analysis. Clin Breast Cancer. 2019;19(4):e556\u201362. https:\/\/doi.org\/10.1016\/j.clbc.2019.04.007.","journal-title":"Clin Breast Cancer"},{"issue":"2","key":"1287_CR63","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.55697","volume":"6","author":"E Mension","year":"2023","unstructured":"Mension E, Alonso I, Angl\u00e8s-Acedo S, et al. Effect of fractional carbon dioxide vs sham laser on sexual function in survivors of breast cancer receiving aromatase inhibitors for genitourinary syndrome of menopause: the LIGHT randomized clinical trial. JAMA Netw Open. 2023;6(2):e2255697. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.55697.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"1287_CR64","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/gme.0000000000001293","volume":"26","author":"C Gordon","year":"2019","unstructured":"Gordon C, Gonzales S, Krychman ML. Rethinking the techno vagina: a case series of patient complications following vaginal laser treatment for atrophy. Menopause. 2019;26(4):423\u20137. https:\/\/doi.org\/10.1097\/gme.0000000000001293.","journal-title":"Menopause"},{"issue":"4","key":"1287_CR65","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/gme.0000000000001221","volume":"26","author":"C Biehl","year":"2019","unstructured":"Biehl C, Plotsker O, Mirkin S. A systematic review of the efficacy and safety of vaginal estrogen products for the treatment of genitourinary syndrome of menopause. Menopause. 2019;26(4):431\u201353. https:\/\/doi.org\/10.1097\/gme.0000000000001221.","journal-title":"Menopause"},{"issue":"4","key":"1287_CR66","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/s0029-7844(98)00175-6","volume":"92","author":"L Cardozo","year":"1998","unstructured":"Cardozo L, Bachmann G, McClish D, Fonda D, Birgerson L. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol. 1998;92(4):722\u20137. https:\/\/doi.org\/10.1016\/s0029-7844(98)00175-6.","journal-title":"Obstet Gynecol"},{"issue":"1","key":"1287_CR67","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejca.2012.07.003","volume":"49","author":"M Fahl\u00e9n","year":"2013","unstructured":"Fahl\u00e9n M, Fornander T, Johansson H, et al. Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur J Cancer. 2013;49(1):52\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2012.07.003.","journal-title":"Eur J Cancer"},{"issue":"3","key":"1287_CR68","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/ppo.0000000000000595","volume":"28","author":"AZ Bluming","year":"2022","unstructured":"Bluming AZ. Hormone replacement therapy after breast cancer: it is time. Cancer J. 2022;28(3):183\u201390. https:\/\/doi.org\/10.1097\/ppo.0000000000000595.","journal-title":"Cancer J"},{"issue":"1","key":"1287_CR69","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s12253-018-00569-x","volume":"26","author":"T Deli","year":"2020","unstructured":"Deli T, Orosz M, Jakab A. Hormone replacement therapy in cancer survivors\u2014review of the literature. Pathol Oncol Res. 2020;26(1):63\u201378. https:\/\/doi.org\/10.1007\/s12253-018-00569-x.","journal-title":"Pathol Oncol Res"},{"issue":"7","key":"1287_CR70","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1093\/jnci\/djn058","volume":"100","author":"L Holmberg","year":"2008","unstructured":"Holmberg L, Iversen OE, Rudenstam CM, et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst. 2008;100(7):475\u201382. https:\/\/doi.org\/10.1093\/jnci\/djn058.","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"1287_CR71","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/jnci\/dji071","volume":"97","author":"E von Schoultz","year":"2005","unstructured":"von Schoultz E, Rutqvist LE. Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. J Natl Cancer Inst. 2005;97(7):533\u20135. https:\/\/doi.org\/10.1093\/jnci\/dji071.","journal-title":"J Natl Cancer Inst"},{"key":"1287_CR72","first-page":"153","volume":"16","author":"R Vassilopoulou-Sellin","year":"1994","unstructured":"Vassilopoulou-Sellin R, Theriault RL. Randomized prospective trial of estrogen-replacement therapy in women with a history of breast cancer. J Natl Cancer Inst Monogr. 1994;16:153\u20139.","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"3","key":"1287_CR73","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1097\/aog.0000000000001351","volume":"127","author":"ACOG Committee Opinion No. 659","year":"2016","unstructured":"ACOG Committee Opinion No. 659. The use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. Obstet Gynecol. 2016;127(3):e93\u20136. https:\/\/doi.org\/10.1097\/aog.0000000000001351.","journal-title":"Obstet Gynecol"},{"issue":"6","key":"1287_CR74","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1200\/jco.2015.64.3809","volume":"34","author":"CD Runowicz","year":"2016","unstructured":"Runowicz CD, Leach CR, Henry NL, et al. American Cancer Society\/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. J Clin Oncol. 2016;34(6):611\u201335. https:\/\/doi.org\/10.1200\/jco.2015.64.3809.","journal-title":"J Clin Oncol"},{"key":"1287_CR75","doi-asserted-by":"publisher","unstructured":"Santos GML, Magalh\u00e3es AO, Teichmann PDV, Wender MCO. Vaginal estrogen therapy for treatment of menopausal genitourinary syndrome among breast cancer survivors: a systematic review and meta-analysis. Rev Bras Ginecol Obstet. 2025. https:\/\/doi.org\/10.61622\/rbgo\/2025rbgo46.","DOI":"10.61622\/rbgo\/2025rbgo46"},{"issue":"2","key":"1287_CR76","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ajog.2019.08.043","volume":"222","author":"KK Crean-Tate","year":"2020","unstructured":"Crean-Tate KK, Faubion SS, Pederson HJ, Vencill JA, Batur P. Management of genitourinary syndrome of menopause in female cancer patients: a focus on vaginal hormonal therapy. Am J Obstet Gynecol. 2020;222(2):103\u201313. https:\/\/doi.org\/10.1016\/j.ajog.2019.08.043.","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"1287_CR77","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3109\/13697137.2014.947254","volume":"18","author":"RJ Santen","year":"2015","unstructured":"Santen RJ. Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels. Climacteric. 2015;18(2):121\u201334. https:\/\/doi.org\/10.3109\/13697137.2014.947254.","journal-title":"Climacteric"},{"issue":"8","key":"1287_CR78","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001500.pub3","volume":"2016","author":"A Lethaby","year":"2016","unstructured":"Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2016;2016(8):Cd001500. https:\/\/doi.org\/10.1002\/14651858.CD001500.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"1287_CR79","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1097\/gme.0000000000001463","volume":"27","author":"RJ Santen","year":"2020","unstructured":"Santen RJ, Mirkin S, Bernick B, Constantine GD. Systemic estradiol levels with low-dose vaginal estrogens. Menopause. 2020;27(3):361\u201370. https:\/\/doi.org\/10.1097\/gme.0000000000001463.","journal-title":"Menopause"},{"issue":"3","key":"1287_CR80","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/gme.0000000000001468","volume":"27","author":"CJ Crandall","year":"2020","unstructured":"Crandall CJ, Diamant A, Santoro N. Safety of vaginal estrogens: a systematic review. Menopause. 2020;27(3):339\u201360. https:\/\/doi.org\/10.1097\/gme.0000000000001468.","journal-title":"Menopause"},{"issue":"5 Suppl","key":"1287_CR81","doi-asserted-by":"publisher","first-page":"685","DOI":"10.6004\/jnccn.2016.0193","volume":"14","author":"ME Melisko","year":"2016","unstructured":"Melisko ME, Narus JB. Sexual function in cancer survivors: updates to the NCCN Guidelines for Survivorship. J Natl Compr Canc Netw. 2016;14(5 Suppl):685\u20139. https:\/\/doi.org\/10.6004\/jnccn.2016.0193.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"1287_CR82","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1001\/jamaoncol.2023.4508","volume":"10","author":"L McVicker","year":"2024","unstructured":"McVicker L, Labeit AM, Coupland CAC, et al. Vaginal estrogen therapy use and survival in females with breast cancer. JAMA Oncol. 2024;10(1):103\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2023.4508.","journal-title":"JAMA Oncol"},{"issue":"6","key":"1287_CR83","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1097\/gme.0000000000001284","volume":"26","author":"SN Bhupathiraju","year":"2018","unstructured":"Bhupathiraju SN, Grodstein F, Stampfer MJ, et al. Vaginal estrogen use and chronic disease risk in the Nurses\u2019 Health Study. Menopause. 2018;26(6):603\u201310. https:\/\/doi.org\/10.1097\/gme.0000000000001284.","journal-title":"Menopause"},{"issue":"3","key":"1287_CR84","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.ajog.2024.10.054","volume":"232","author":"ME Beste","year":"2025","unstructured":"Beste ME, Kaunitz AM, McKinney JA, Sanchez-Ramos L. Vaginal estrogen use in breast cancer survivors: a systematic review and meta-analysis of recurrence and mortality risks. Am J Obstet Gynecol. 2025;232(3):262-270.e1. https:\/\/doi.org\/10.1016\/j.ajog.2024.10.054.","journal-title":"Am J Obstet Gynecol"},{"issue":"10","key":"1287_CR85","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1093\/jnci\/djac112","volume":"114","author":"S Cold","year":"2022","unstructured":"Cold S, Cold F, Jensen MB, Cronin-Fenton D, Christiansen P, Ejlertsen B. Systemic or vaginal hormone therapy after early breast cancer: a Danish observational cohort study. J Natl Cancer Inst. 2022;114(10):1347\u201354. https:\/\/doi.org\/10.1093\/jnci\/djac112.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"1287_CR86","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10549-012-2198-y","volume":"135","author":"I Le Ray","year":"2012","unstructured":"Le Ray I, Dell\u2019Aniello S, Bonnetain F, Azoulay L, Suissa S. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study. Breast Cancer Res Treat. 2012;135(2):603\u20139. https:\/\/doi.org\/10.1007\/s10549-012-2198-y.","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"1287_CR87","doi-asserted-by":"publisher","first-page":"e731","DOI":"10.1016\/j.clbc.2019.07.007","volume":"19","author":"RT Pavlovi\u0107","year":"2019","unstructured":"Pavlovi\u0107 RT, Jankovi\u0107 SM, Milovanovi\u0107 JR, et al. The safety of local hormonal treatment for vulvovaginal atrophy in women with estrogen receptor-positive breast cancer who are on adjuvant aromatase inhibitor therapy: meta-analysis. Clin Breast Cancer. 2019;19(6):e731\u201340. https:\/\/doi.org\/10.1016\/j.clbc.2019.07.007.","journal-title":"Clin Breast Cancer"},{"issue":"12","key":"1287_CR88","doi-asserted-by":"publisher","first-page":"e1846","DOI":"10.1634\/theoncologist.2020-0417","volume":"25","author":"P S\u00e1nchez-Rovira","year":"2020","unstructured":"S\u00e1nchez-Rovira P, Hirschberg AL, Gil-Gil M, Bermejo-De Las Heras B, Nieto-Magro C. A phase II prospective, randomized, double-blind, placebo-controlled and multicenter clinical trial to assess the safety of 0.005% estriol vaginal gel in hormone receptor-positive postmenopausal women with early stage breast cancer in treatment with aromatase inhibitor in the adjuvant setting. Oncologist. 2020;25(12):e1846-1854. https:\/\/doi.org\/10.1634\/theoncologist.2020-0417.","journal-title":"Oncologist"},{"issue":"1","key":"1287_CR89","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1097\/gme.0b013e3181e195a6","volume":"18","author":"F Labrie","year":"2011","unstructured":"Labrie F, Martel C, Balser J. Wide distribution of the serum dehydroepiandrosterone and sex steroid levels in postmenopausal women: role of the ovary? Menopause. 2011;18(1):30\u201343. https:\/\/doi.org\/10.1097\/gme.0b013e3181e195a6.","journal-title":"Menopause"},{"issue":"12","key":"1287_CR90","doi-asserted-by":"publisher","first-page":"4588","DOI":"10.1210\/jc.2017-01474","volume":"102","author":"N Hetem\u00e4ki","year":"2017","unstructured":"Hetem\u00e4ki N, Savolainen-Peltonen H, Tikkanen MJ, et al. Estrogen metabolism in abdominal subcutaneous and visceral adipose tissue in postmenopausal women. J Clin Endocrinol Metab. 2017;102(12):4588\u201395. https:\/\/doi.org\/10.1210\/jc.2017-01474.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"1287_CR91","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1097\/gme.0000000000001238","volume":"25","author":"F Labrie","year":"2018","unstructured":"Labrie F, Archer DF, Koltun W, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause. 2018;25(11):1339\u201353. https:\/\/doi.org\/10.1097\/gme.0000000000001238.","journal-title":"Menopause"},{"key":"1287_CR92","unstructured":"Intrarosa [package insert]. Quebec City: Endoceuticals; 2016."},{"key":"1287_CR93","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jsbmb.2016.03.016","volume":"159","author":"C Martel","year":"2016","unstructured":"Martel C, Labrie F, Archer DF, et al. Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks. J Steroid Biochem Mol Biol. 2016;159:142\u201353. https:\/\/doi.org\/10.1016\/j.jsbmb.2016.03.016.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"3","key":"1287_CR94","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1515\/hmbci-2015-0044","volume":"25","author":"C Bouchard","year":"2016","unstructured":"Bouchard C, Labrie F, Derogatis L, et al. Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study. Horm Mol Biol Clin Investig. 2016;25(3):181\u201390. https:\/\/doi.org\/10.1515\/hmbci-2015-0044.","journal-title":"Horm Mol Biol Clin Investig."},{"issue":"12","key":"1287_CR95","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1097\/gme.0000000000000470","volume":"22","author":"DJ Portman","year":"2015","unstructured":"Portman DJ, Labrie F, Archer DF, et al. Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women. Menopause. 2015;22(12):1289\u201395. https:\/\/doi.org\/10.1097\/gme.0000000000000470.","journal-title":"Menopause"},{"issue":"2","key":"1287_CR96","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s00520-017-3878-2","volume":"26","author":"DL Barton","year":"2018","unstructured":"Barton DL, Sloan JA, Shuster LT, et al. Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer. 2018;26(2):643\u201350. https:\/\/doi.org\/10.1007\/s00520-017-3878-2.","journal-title":"Support Care Cancer"},{"issue":"4","key":"1287_CR97","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s00520-017-3960-9","volume":"26","author":"DL Barton","year":"2018","unstructured":"Barton DL, Shuster LT, Dockter T, et al. Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance). Support Care Cancer. 2018;26(4):1335\u201343. https:\/\/doi.org\/10.1007\/s00520-017-3960-9.","journal-title":"Support Care Cancer"},{"issue":"5","key":"1287_CR98","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1080\/13697137.2022.2050208","volume":"25","author":"E Mension","year":"2022","unstructured":"Mension E, Alonso I, Cebrecos I, et al. Safety of prasterone in breast cancer survivors treated with aromatase inhibitors: the VIBRA pilot study. Climacteric. 2022;25(5):476\u201382. https:\/\/doi.org\/10.1080\/13697137.2022.2050208.","journal-title":"Climacteric"},{"key":"1287_CR99","doi-asserted-by":"publisher","DOI":"10.3390\/ph16040550","author":"L Merlino","year":"2023","unstructured":"Merlino L, D\u2019Ovidio G, Matys V, et al. Therapeutic choices for genitourinary syndrome of menopause (GSM) in breast cancer survivors: a systematic review and update. Pharmaceuticals (Basel). 2023. https:\/\/doi.org\/10.3390\/ph16040550.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"2","key":"1287_CR100","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/j.1471-0528.1998.tb10056.x","volume":"105","author":"MB Hodgins","year":"1998","unstructured":"Hodgins MB, Spike RC, Mackie RM, MacLean AB. An immunohistochemical study of androgen, oestrogen and progesterone receptors in the vulva and vagina. Br J Obstet Gynaecol. 1998;105(2):216\u201322. https:\/\/doi.org\/10.1111\/j.1471-0528.1998.tb10056.x.","journal-title":"Br J Obstet Gynaecol"},{"issue":"4","key":"1287_CR101","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/s0015-0282(02)04923-3","volume":"79","author":"JR Berman","year":"2003","unstructured":"Berman JR, Almeida FG, Jolin J, Raz S, Chaudhuri G, Gonzalez-Cadavid NF. Correlation of androgen receptors, aromatase, and 5-\u03b1 reductase in the human vagina with menopausal status. Fertil Steril. 2003;79(4):925\u201331. https:\/\/doi.org\/10.1016\/s0015-0282(02)04923-3.","journal-title":"Fertil Steril"},{"issue":"6","key":"1287_CR102","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1097\/gme.0000000000001052","volume":"25","author":"RJ Bell","year":"2018","unstructured":"Bell RJ, Rizvi F, Islam RM, Davis SR. A systematic review of intravaginal testosterone for the treatment of vulvovaginal atrophy. Menopause. 2018;25(6):704\u20139. https:\/\/doi.org\/10.1097\/gme.0000000000001052.","journal-title":"Menopause"},{"issue":"3","key":"1287_CR103","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1111\/j.1743-6109.2009.01667.x","volume":"7","author":"C Raghunandan","year":"2010","unstructured":"Raghunandan C, Agrawal S, Dubey P, Choudhury M, Jain A. A comparative study of the effects of local estrogen with or without local testosterone on vulvovaginal and sexual dysfunction in postmenopausal women. J Sex Med. 2010;7(3):1284\u201390. https:\/\/doi.org\/10.1111\/j.1743-6109.2009.01667.x.","journal-title":"J Sex Med"},{"issue":"7","key":"1287_CR104","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1097\/gme.0000000000000613","volume":"23","author":"T Fernandes","year":"2016","unstructured":"Fernandes T, Costa-Paiva LH, Pedro AO, Baccaro LF, Pinto-Neto AM. Efficacy of vaginally applied estrogen, testosterone, or polyacrylic acid on vaginal atrophy: a randomized controlled trial. Menopause. 2016;23(7):792\u20138. https:\/\/doi.org\/10.1097\/gme.0000000000000613.","journal-title":"Menopause"},{"issue":"4","key":"1287_CR105","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1634\/theoncologist.2010-0435","volume":"16","author":"S Witherby","year":"2011","unstructured":"Witherby S, Johnson J, Demers L, et al. Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I\/II study. Oncologist. 2011;16(4):424\u201331. https:\/\/doi.org\/10.1634\/theoncologist.2010-0435.","journal-title":"Oncologist"},{"issue":"11","key":"1287_CR106","doi-asserted-by":"publisher","first-page":"4146","DOI":"10.1210\/jc.2018-01345","volume":"103","author":"SR Davis","year":"2018","unstructured":"Davis SR, Robinson PJ, Jane F, White S, White M, Bell RJ. Intravaginal testosterone improves sexual satisfaction and vaginal symptoms associated with aromatase inhibitors. J Clin Endocrinol Metab. 2018;103(11):4146\u201354. https:\/\/doi.org\/10.1210\/jc.2018-01345.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1287_CR107","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1001\/jamaoncol.2016.3904","volume":"3","author":"ME Melisko","year":"2017","unstructured":"Melisko ME, Goldman ME, Hwang J, et al. Vaginal testosterone cream vs estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for early-stage breast cancer: a randomized clinical trial. JAMA Oncol. 2017;3(3):313\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2016.3904.","journal-title":"JAMA Oncol"},{"issue":"7","key":"1287_CR108","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1097\/gme.0000000000000624","volume":"23","author":"N Eigeliene","year":"2016","unstructured":"Eigeliene N, Kangas L, Hellmer C, Kauko T, Erkkola R, H\u00e4rk\u00f6nen P. Effects of ospemifene, a novel selective estrogen-receptor modulator, on human breast tissue ex vivo. Menopause. 2016;23(7):719\u201330. https:\/\/doi.org\/10.1097\/gme.0000000000000624.","journal-title":"Menopause"},{"key":"1287_CR109","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.maturitas.2018.11.017","volume":"121","author":"V Di Donato","year":"2019","unstructured":"Di Donato V, Schiavi MC, Iacobelli V, et al. Ospemifene for the treatment of vulvar and vaginal atrophy: a meta-analysis of randomized trials. Part II: evaluation of tolerability and safety. Maturitas. 2019;121:93\u2013100. https:\/\/doi.org\/10.1016\/j.maturitas.2018.11.017.","journal-title":"Maturitas"},{"issue":"1","key":"1287_CR110","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1089\/jwh.2017.6385","volume":"27","author":"JA Simon","year":"2018","unstructured":"Simon JA, Altomare C, Cort S, Jiang W, Pinkerton JV. Overall safety of ospemifene in postmenopausal women from placebo-controlled phase 2 and 3 trials. J Womens Health. 2018;27(1):14\u201323. https:\/\/doi.org\/10.1089\/jwh.2017.6385.","journal-title":"J Womens Health"},{"issue":"2","key":"1287_CR111","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3109\/13697137.2013.834493","volume":"17","author":"SR Goldstein","year":"2014","unstructured":"Goldstein SR, Bachmann GA, Koninckx PR, Lin VH, Portman DJ, Ylikorkala O. Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy. Climacteric. 2014;17(2):173\u201382. https:\/\/doi.org\/10.3109\/13697137.2013.834493.","journal-title":"Climacteric"},{"key":"1287_CR112","unstructured":"Osphena [package insert]. Princeton: Duchesnay USA; 2013."},{"issue":"3","key":"1287_CR113","doi-asserted-by":"publisher","first-page":"170","DOI":"10.6118\/jmm.24011","volume":"30","author":"E Pennacchini","year":"2024","unstructured":"Pennacchini E, Dall\u2019Alba R, Iapaolo S, et al. Treatment of genitourinary syndrome of menopause in breast cancer and gynecologic cancer survivors: retrospective analysis of efficacy and safety of vaginal estriol, vaginal dehydroepiandrosterone and ospemifene. J Menopausal Med. 2024;30(3):170\u20138. https:\/\/doi.org\/10.6118\/jmm.24011.","journal-title":"J Menopausal Med"},{"key":"1287_CR114","unstructured":"Senshio [summary of product characteristics]. Amsterdam: Shionogi; 2015."}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-026-01287-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-026-01287-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-026-01287-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T03:02:08Z","timestamp":1773802928000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-026-01287-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":114,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1287"],"URL":"https:\/\/doi.org\/10.1007\/s40266-026-01287-9","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"19 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr Juliana Kling is a consultant for Bayer and Elsevier. She receives CME and non-CME honorarium for AiCME, City of Mesa, Paradise Valley Country Club, EPG Health, Vindico Medical Education, Arizona Public Services, WebMD, and Evolve Medical Education LLC. Dr Dewonna Ferguson and Dr Holly Pederson declare that they have no conflicts of interest relevant to the content of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article is a narrative review based on previously published literature. No new data were generated or analyzed during the current study. Data sharing is not applicable to this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors. Ethics approval was not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Dr Juliana Kling conceived the idea for the article. Dr Dewonna Ferguson performed the literature search and drafted the original manuscript. Drs Holly Pederson and Juliana Kling critically revised the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}